Fosun Tweaks Gland Deal Amid Limbo In India

China’s Fosun group isn’t backing off from its $1bn-plus buyout of Gland Pharma and will now pursue a tweaked version of the original deal that technically qualifies for automatic approval under Indian rules. Whether that means smooth sailing hereon remains unclear.

Big Fish
WILL FOSUN'S ACQUISITION OF GLAND MOVE SMOOTHLY AHEAD HEREON?

China’s Fosun group has agreed to pare its proposed holding in the Indian injectables firm Gland Pharma Ltd. as part of certain revised terms pertaining to the mega deal, currently in limbo in India.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip